Liquid Biopsies Congress

When

2019年10月10-11日
Registration from 8am

Where

英国、ロンドン
London Heathrow Marriott Hotel

Liquid Biopsies Congress
-リキッドバイオプシー学会-
開催日:2019年10月10-11日
開催地:英国、ロンドン、London Heathrow Marriott Hotel
Choose your language
Traditional Chinese
Simplified Chinese
Korean
English

更新通知サービス
更新履歴
2019/08/23
講演者・スポンサー更新
2019/07/26
アジェンダ・講演者・スポンサー更新
2019/06/20
スポンサー更新
2019/05/22
スポンサー更新

Liquid Biopsies Congress

診断、予後、セラノスティクスへのリキッドバイオプシーの応用

定量PCR (qPCR) 、デジタルPCR、次世代シーケンシング (NGS) などの技術を利用してリキッドバイオプシーの開発を加速させ、がんの主要な非侵襲的診断検査へと発展させていくための取り組みについて学ぶことができます。今度の学会では、セルフリーDNA (cfDNA) 、血中循環腫瘍細胞 (CTC) 、細胞外小胞 (EV) などの血中バイオマーカーが焦点となります。

“I met leading companies/biomarker developers at one place sharing cutting edge technologies”.

“Interesting mixture of topics; possibility to discuss with the attendees”

“Learned a lot from some of the talks”

2019年10月10日(木) – リキッドバイオプシー:手法と技術


基調講演: がんの汎用バイオマーカーに関する研究の現状
MATT TRAU, Professor of Chemistry, Deputy Director and Co-Founder of AIBN, University of Queensland, Australia
Epigenetic reprogramming in cancer genomes creates a distinct methylation landscape encompassing clustered methylation at regulatory regions separated by large intergenic tracks of hypomethylated regions. This methylation landscape that we referred to as Methylscape is displayed by most cancer types, thus may serve as a universal cancer biomarker. We examine the effect of levels and genomic distribution of methylcytosines on the physicochemical properties of DNA to detect the Methylscape biomarker. We find that DNA polymeric behaviour is strongly affected by differential patterning of methylcytosine, leading to fundamental differences in DNA solvation and DNA-gold affinity between cancerous and normal genomes. We exploit these Methylscape differences to develop simple, highly sensitive and selective electrochemical or colorimetric one-step assays for the detection of cancer. These assays are quick, i.e., analysis time≤10minutes, and require minimal sample preparation and small DNA input from either solid or liquid biopsies.

基調講演: がんおよびその他の疾患におけるリキッドバイオプシーの実現
SIMON LUCAS, Innovation Field Explorer, Merck KGaA
The early detection of life-threatening conditions as well as the selection of individualized treatment options for affected patients will have significant potential to disrupt our current public health sectors. Recently, alternatives to traditional tissue biopsy, such as liquid or breath biopsy, have emerged as attractive tools for the detection and management of various diseases and especially in the therapeutic area of oncology. While cancer detection with liquid biopsy is gaining acceptance, other indications often still lack a non-invasive diagnostic test, even though precision medicine is viewed as an important concept in indications outside oncology. This talk highlights the opportunities of liquid biopsy in cancer and beyond as well as our efforts at Merck to address challenges in the field with new enabling technologies.

PRESENTATION


Morning Refreshments / Poster Presentations / One-to-One Meetings


Considerations when analyzing cell-free tumor DNA
ANDERS STAHLBERG, Associate Professor, University of Gothenburg, Sweden
• Analysis of circulating cell-free tumor DNA (ctDNA) in liquid biopsies offers new means for early cancer diagnostics, real-time monitoring of treatment efficiency and detection of relapse. Despite its potential use ctDNA remains challenging to detect and to quantify as it represents only a small fraction of all cell-free DNA.
• We have developed SiMSen-Seq, that allows allele frequencies < 0.1% to be detected. SiMSen-Seq is simple to perform, flexible in multiplexing and requires minimal DNA input.
• Here, we discuss important considerations for ctDNA analysis in plasma, including all experimental steps from sampling to data interpretation. Furthermore, the use of quality control assays enables the development of robust and standardized workflows that facilitate the implementation of ctDNA analysis into clinical routine.

Standardized analysis of extracellcular vesicles in liquid biopsies
AN HENDRIX, Assistant Professor, University of Ghent, Belgium
The identification of extracellular vesicle (EV)-associated biomarkers is challenging owing to the complexity of liquid biopsies. We 1) performed quality control studies to identify the impact of (pre-) analytical variables on biomarker identification, 2) developed reference materials to ensure standardized EV measurements, and 3) created EV-TRACK to stimulate researchers to put experimental guidelines into practice. This combined expertise boosted the identification of bacterial EV in the systemic circulation of patients with intestinal barrier dysfunction.

PRESENTATION


Lunch


Innovation in Research: From Protein Array to Companion Diagnostics to Profiling of Adverse Events
DOLORES CAHILL, Professor of Translational Science, University College Dublin, Ireland
Overview of profiling the autoantibody repertoire on high content protein arrays and using this approach to identify biomarkers, and develop diagnostics and companion diagnostics.

Clinical utility of CTC and ctDNA in metastatic and neo/adjuvant setting of breast cancer
JEAN-YVES PIERGA, Institut Curie, Department of Medical Oncology and Circulating Tumor Biomarkers Laboratory, SiRIC, Universite Paris Descartes, France
Circulating tumor cells (CTCs) have been identified as potential blood-based biomarker capable of providing prognostic and predictive information in breast cancer. Their applications include early diagnosis, prognostic assessment, detection of minimal residual disease, early detection of cancer relapse and management of metastatic disease. The clinical validity of the CTCbased liquid biopsy has been already assessed by numerous studies. Pooled analysis of large clinical data set in adjuvant, neoadjuvant and metastatic setting are now available. Recent results of clinical trial could support their clinical utility. The potential applications for circulating tumour DNA (ctDNA) in early and metastatic setting include prognosis assessment before treatment initiation, early assessment of treatment efficacy and help to guide personalized therapies.

PRESENTATION
ROBERT NEELY (Reserved), Associate Director, Pharmacodiagnostics, BMS


Afternoon Refreshments / Poster Presentations / One-to-One Meetings


Translating liquid biopsies into routine care
PANEL DISCUSSION – Speakers include:

KATARZYNA WITKOWSKA
Commercial Partnerships Manager, Genomics England, UK

KAREN SPINK
Innovation Lead - Precision Medicine, Innovate UK
ALEXANDRE HARLE
Assistant Professor, Molecular Biologist, Institut de Cancerologie de Lorraine, France
IWANKA KOZAREWA
Senior Scientist, AstraZeneca, UK
BERNHARD POLZER
Head Cellular and Molecular Diagnostics, Division Personalized Tumor Therapy, Fraunhofer-Institute for
Toxicology and Experimental Medicine ITEM-R, Germany
SIMON LUCAS
Innovation Field Explorer, Merck KGaA, Germany


Networking Drinks Reception


2019年10月11日(金) - 臨床応用

基調講演: がん検出のためのリキッドバイオプシー検査
DIANA ANDERSON, Established Chair, Biomedical Sciences, University of Bradford, UK
There appeared to be no single test to identify cancer in general, but we have developed such an assay. In this modified patented Comet assay, we investigated peripheral lymphocytes from blood of 208 individuals, known as the Lymphocyte Genome Sensitivity (LGS) test. Ninety four individuals were controls. All cancers tested exhibited comparable responses. Analyses of Receiver Operating Characteristic (ROC) curves, of mean log Olive tail moments for cancer alone versus controls alone, the area under the curve was 0.93. By varying the threshold for test positivity, its sensitivity or specificity can approach 100% whilst maintaining acceptable
complementary measures. Since lymphocytes in blood only are examined, and the test has been repeated with over 900 individuals with equally valid responses, this is a useful Liquid Biopsy assay.

Liquid biopsies on the road to clinical utility
RALPH GRAESER, Senior Translational Medicine Expert, Boehringer Ingelheim
• Use of liquid biopsies in the clinic: diagnostic, prognostic, predictive?
• CTCs vs ctDNA: one or the other - or both?
• CANCER-id - a public-private partnership with the goal to standardize liquid biopsy protocols for clinical use


Morning Refreshments / Poster Presentations / One-to-One Meetings


Novel digital PCR and mutation enrichment technologies for the analysis of clinically relevant DNA alterations in liquid biopsies
MIKE MAKRIGIORGOS, Professor of Radiation Oncology, Dana Farber Cancer Institute and Harvard Medical School, USA
With the increasing interest in treatment assessment using liquid biopsy and circulating DNA, sensitive and multiplexed detection of tumor-derived alterations in blood are desirable. We provide novel forms of digital PCR, as well as mutation enrichment-based real time PCR methods that (a) enable several orders of magnitude improvement of detecting mutations or microsatellite instability than currently possible; (b) are highly multiplex-able; (c) reduce cost of analysis. Application in circulating DNA from clinical cancer samples will be presented.

A targeted multi-analyte liquid biopsy to identify early stage gynecologic cancers
JOHN MARTIGNETTIProfessor, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, and Director, Laboratory of Translational Research, Western Connecticut Health Network, USA
Overwhelmingly the power and success of “liquid biopsy” has been focused on issues related to advanced disease in already diagnosed patients under active treatment. We demonstrate an approach and the feasibility of using a targeted liquid biopsy approach for detecting early stage gynecologic cancers by combining analysis of both DNA and proteins.


Lunch


CTC analysis: Latest advancements and clinical applications
EVI LIANIDOU, Professor of Analytical Chemistry - Clinical Chemistry, University of Athens, Greece
• Liquid biopsy provides a valuable source of biomarkers through simple and minimally invasive serial blood draws and represents a highly dynamic diagnostic, prognostic and theranostic tool for the management of cancer patients.
• Circulating tumor cells (CTCs) are major players in liquid biopsy and their molecular characterization offers
an exciting approach to monitor the efficacy of systemic therapies in real-time, unravel the biology of cancer cell dissemination, understand resistance to established therapies and identify gene targets and signalling pathways relevant to therapeutic interventions.
• Single-cell CTC analysis is a powerful tool to understand tumor heterogeneity and the mechanisms involved in cancer progression with potential implications for improving treatment strategies.
• This lecture will be focused on the latest developments in the detection and molecular characterization of CTCs, and their clinical applications in many types of cancer.

Prognostic and predictive value of circulating methylated DNA in metastatic colorectal cancer patients treated with regorafenib
LUDOVIC BARAULT, Senior Research Associate, Candiola Cancer Institute and the University of Torino, Italy
• Regorafenib is associated with improved progression free survival (PFS) in a subset of metastatic colorectal cancer
(mCRC) patients and no biomarkers of efficacy are available for this drug which is often associated with many toxicities.
• We previously found an association between circulating methylated DNA and outcome in chemotherapy treated mCRC patients and we hypothesized that such biomarker could be used to identify cases most likely to benefit from regorafenib (i.e. patients with PFS longer than 4 months).
• Assessment of pre and on treatment blood samples confirmed the prognostic value of circulating methylated DNA and suggest its use as biomarker for regorafenib since it may predict unresponsiveness to the treatment.

PRESENTATION
ANDREAS HAUSER, Staff Scientist, LMU, Germany


Chair’s Closing Remarks / Conference Close


 

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

講演者

アジェンダ

350人以上の専門家が集まるこの学会は、疾病の迅速な検出、早期診断、疾病や治療反応のモニタリング強化などを可能にする侵襲性の低い生検技術の開発に取り組んでおられる方々を対象としたものです。

アジェンダのダウンロード (PDF)

スポンサー

すべてのスポンサーのリスト

開催地

London Heathrow Marriott Hotel

London Heathrow Marriott900

Bath Road, Harlington, Hayes, Middlesex, UB3 5AN

ポスター発表

ポスター発表は、休憩時間中だけではなく、分科会セッションと同時進行でも行われます。製薬会社や研究機関の研究者が作成したポスターは、いずれも学会事務局の承認を得たうえで、会場内の所定のエリアに掲示されます。

また学会閉幕後には、ポスター発表の要旨をまとめた電子書籍が出席者全員に配布されることになっており、ポスターを.pdf形式のファイルにして公表することもできます(希望者のみ)。

ポスター発表は、出資や雇用の機会を求めておられる方にとっても、単に同じような考えの研究者や同じテーマに取り組んでいる研究グループに成果を披露したいと考えておられる方にとっても、会場内で多くの注目を集めることができる貴重な機会となります。

ポスター発表を行うには、学会の出席者として参加登録する必要があります。ポスターを掲示できるスペースは限られており、審査を通過して参加登録された方から先着順に受け付けますので、早期のお申し込みをお勧めします。

企業に所属されている方がポスター発表を行う場合、100ポンドの管理費を請求させていただきます。このなかには、ポスター発表のエリアを確保するための費用やデイスプレイボードの費用、各種案内の費用などが含まれます。なお、研究機関や非営利組織の発表者は無料です。

ポスター発表の申込方法

専用のフォームにご記入のうえ、2019年9月20日までに提出してください。期日前であっても、スペースがすべて埋まった時点で募集を締め切りますので、早期のお申込みをお勧めします。ご不明な点は、お問い合わせください。

学会のスポンサー

スポンサーの募集

この学会のスポンサーや出展者になることにより、打ち解けた雰囲気のなか専門家と意見を交換しながら、さまざまな組織の代表と公式、非公式の会談を行って提携関係を構築していくチャンスを手にすることができます。

また各種のスポンサーパッケージも用意されており、多様な選択肢の中から予算や事業面のニーズに合ったものを選ぶことで大きな投資収益を得ることができます。

これ以外の方法でこの学会のスポンサーとなったり、ブランディング活動を展開したりすることを検討されている方も、どうぞお気軽にご相談ください。それぞれのニーズに合ったサービスを提案させていただきます。

事前に予約可能な20分の個別会談枠

スポンサーと出展者は、メインカンファレンスの分科会セッション中に設定されている20分ずつの個別会談枠を事前に予約して、希望する相手に会うことができます。会期中は、Global Engageのチームが会場に常駐し、時間通りに会談を行うことができるようお手伝いいたします。

メインカンファレンス前後のワークショップ

メインカンファレンスの前後に、特定のテーマに関心を持つ方々を対象とした半日あるいは全日のワークショップを開催することができます。Global Engageは、ワークショップについての広報活動を展開し、十分な出席者を確保することができるよう支援します。

学会開幕前のマーケティングとブランディング

Global Engageのデータベースを利用してマーケティングを展開することが可能であり、ポスターを掲示したり、休憩や昼食会、レセプション、ポスターセッションのスポンサーになったりすることでブランド認知度を高めることもできます。また、出席者に配布するランヤードや学会資料のバッグにロゴを印刷するといったブランディングのための追加オプションも用意されています。

出展

会期中、会場内に設けられる専用の展示会エリアですべての出席者に技術や製品を披露することができます。展示会エリアは、休憩や昼食、1日目夕方に行われるレセプションの会場にもなります。

講演

講演の形態

  • 30分間の講演
  • 30分間のパネルディスカッションに司会進行役あるいはパネリストとして参加
  • 学会のプログラムのなかで1時間のワークショップを開催
スポンサーの募集

詳細は株式会社グローバルインフォメーションまでお問い合わせください。

ビザを含む渡航手続き、展示品等の通関手続きは各出展社様ご自身の責任にて行って頂くようお願い申し上げます。

出展関連のお手配(会社紹介、会社ロゴ、また参加者一覧の提出等の出展社情報登録、ブース装飾・備品発注、展示品の搬入出・ブース周り書類提出、損害保険など)に関しては、お手数ですが直接、主催者へご連絡頂ければ幸いです。

ご旅行(宿泊、航空券)、現地通訳、渡航・損害保険加入などについてはそれぞれ専門の業者をご案内させて頂きます。

Liquid Biopsies Congressのスポンサーの詳細については、お問い合わせください。

出席者、パッケージ、新たな募集などについての詳細な情報は、お問い合わせください。このイベントについて評価を行うために必要となる情報をお送りいたします。

メディアパートナー

  • 247 Updates
  • Biocompare
  • Bentham Science
  • Biotechgate
  • EIN Presswire
  • Global Information
  • Pharma Journalist
  • PharmaVOICE
  • SciDoc Publishers
  • Pharmaceutical Tech
 
メール配信サービス